Semler Scientific Agrees to $30 Million Settlement Over Health Care Fraud Claims

September 17, 2025 - 22:28

Semler Scientific has reached a significant settlement with the Department of Justice (DOJ), agreeing to pay nearly $30 million to resolve allegations of health care fraud linked to its QuantaFlo test for peripheral artery disease. The settlement comes as part of a broader investigation into the company’s marketing practices and the accuracy of its diagnostic claims.

The QuantaFlo test, which is designed to assess blood flow and assist in the diagnosis of peripheral artery disease, has been scrutinized for its effectiveness and the manner in which it was promoted to health care providers. The DOJ's investigation focused on whether Semler engaged in improper practices that misled both patients and healthcare professionals regarding the test's capabilities.

As part of the settlement, Semler has not admitted to any wrongdoing but has agreed to implement compliance measures to enhance its marketing and sales practices. This resolution marks a pivotal moment for the company as it seeks to restore its reputation in the health care industry while ensuring adherence to federal regulations moving forward.